What is the standard of care for locally advanced Colorectal Cancer according to NCCN guidelines

Standard of Care for Locally Advanced Colorectal Cancer (NCCN Guidelines)

What "Locally Advanced" Means

Locally advanced colorectal cancer means the tumor has grown deeply into or through the colon wall and/or involves nearby lymph nodes, but hasn't spread to distant organs like the liver or lungs. This is typically Stage III disease.

---

Treatment Approach: Surgery + Chemotherapy

According to the NCCN Guidelines for Colon Cancer (Version 5.2025), the standard approach for locally advanced colon cancer involves:

Primary Treatment: Surgery First

• Colectomy (surgical removal of the affected colon segment) with en bloc removal of regional lymph nodes (removing the lymph nodes attached to that area)
• Surgeons must remove at least 12 lymph nodes to properly stage the cancer
• The goal is complete resection (R0 resection), meaning all visible cancer is removed with clear margins

Adjuvant Chemotherapy (After Surgery)

After surgery heals, patients typically receive chemotherapy. The standard regimens include:

Preferred Options:

• FOLFOX (fluorouracil + leucovorin + oxaliplatin)
• CAPEOX (capecitabine + oxaliplatin)

Alternative Option:

• Capecitabine or 5-FU/leucovorin alone (for patients who cannot tolerate oxaliplatin)

Duration: Typically 24 weeks (about 6 months) of treatment

---

Special Considerations by Tumor Genetics

Your treatment may be tailored based on specific genetic markers:

For dMMR/MSI-H Tumors (deficient mismatch repair or microsatellite instability-high)

According to NCCN Guidelines, patients with these mutations may be candidates for:

• Checkpoint inhibitor immunotherapy (preferred option)
• Combined with chemotherapy in some cases
• Examples include nivolumab, pembrolizumab, or dostarlimab

For BRAF V600E Mutations

• Targeted therapy combinations may be considered
• Encorafenib combined with EGFR inhibitors (cetuximab or panitumumab) plus chemotherapy

For RAS/NRAS/BRAF Wild-Type (WT) Tumors

• EGFR inhibitors (cetuximab or panitumumab) may be added to chemotherapy for left-sided tumors

---

Neoadjuvant Therapy (Before Surgery)

For clinical T4b disease (tumor invading adjacent structures) or bulky nodal disease, NCCN Guidelines recommend considering:

• Neoadjuvant chemotherapy (FOLFOX or CAPEOX) given BEFORE surgery
• This may help shrink the tumor and make surgery more effective
• Can be combined with radiation therapy in selected cases

---

Key Surgical Principles

According to NCCN Guidelines:

✓ Minimally invasive approaches (laparoscopic or robot-assisted surgery) are acceptable if:

• The surgeon has experience with these techniques
• Proper tumor localization is performed beforehand
• Thorough abdominal exploration can be completed

✗ Minimally invasive surgery is generally NOT recommended for:

• Locally advanced cancers invading adjacent structures
• Acute bowel obstruction or perforation

---

Post-Treatment Surveillance

After completing treatment, NCCN Guidelines recommend:

• Physical exams at regular intervals
• CEA blood tests (carcinoembryonic antigen - a tumor marker)
• CT imaging of chest, abdomen, and pelvis
• Colonoscopy to check for recurrence
• Frequency depends on stage and risk factors

---

Important Genetic Testing

Before starting treatment, NCCN Guidelines recommend testing for:

• Mismatch repair (MMR) status or Microsatellite instability (MSI)
• KRAS, NRAS, and BRAF mutations
• HER2 amplification (in some cases)
• DPYD genetic variants (before fluoropyrimidine therapy like 5-FU or capecitabine) - the FDA now recommends this testing due to risk of severe toxicity

---

Questions to Ask Your Oncology Team

1. What is my tumor's stage and genetic profile (MMR/MSI, KRAS, BRAF status)?
2. Am I a candidate for neoadjuvant therapy before surgery, or will I have surgery first?
3. Which chemotherapy regimen do you recommend for me, and why?
4. Should I be tested for DPYD variants before starting fluoropyrimidine therapy?
5. If my tumor has specific mutations (dMMR/MSI-H, BRAF), am I eligible for immunotherapy or targeted therapy?
6. What is my expected treatment timeline, and what are the potential side effects?
7. How will you monitor me after treatment is complete?

---

Key Sources

This information is based on:

• NCCN Guidelines for Colon Cancer, Version 5.2025 (updated [date removed])
• Specifically the sections on locally advanced, resectable colon cancer and adjuvant treatment recommendations

The NCCN (National Comprehensive Cancer Network) updates these guidelines regularly based on the latest clinical evidence, so your oncologist may reference the most current version available.

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.